Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke

Platelets

Volumn 17, Issue 2, 2006, Pages 100-104

  Zhao, Lian ^a   Gray, Laura ^a   Leonardi Bee, Jo ^a   Weaver, Chris S ^a   Heptinstall, Stan ^a   Bath, Philip M W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aspirin; Clopidogrel; Dipyridamole; Leucocyte; Platelet; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; CYCLIC GMP; DIPYRIDAMOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD VESSEL FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MEASUREMENT; METABOLITE; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; ARTERIOSCLEROSIS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDIES; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET COUNT; PLATELET-DERIVED GROWTH FACTOR; SOLUBILITY; TICLOPIDINE; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 31544464695     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500235966     Document Type: Article

References (40)

1. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
2. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener H-C, Guiraud-Chaumeil B, Sivenius J, Yatsu F, Dewey ME, and Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. Stroke 2005;36:162-168.
3. Libby P, Simon DI. Inflammation and thrombosis: The clot thickens. Circulation 2001;103:1718-1720.
4. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316.
5. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin antithrombin complex formation in rat hindquartes via heparin-like molecules bound to the endothelium. J Clin Invest 1984;74:341.
6. Aukrust P, Damas JK, Solum NO. Soluble CD40 ligand and platelets: Self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol 2004;43:2326-2328.
7. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999;147:213-125.
8. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:II2-10.
9. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of c-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
10. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002;44:469-478.
11. Devaraj S, Xu DY, Jialal I. C-Reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107: 398-404.
12. Ruggeri ZM. Role of von Willebrand factor in platelet thrombus formation. Ann Med 2000;32(Suppl 1):2-9.
13. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
14. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983;306:174-176.
15. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001;134:353-358.
16. Zhao L, Fletcher S, Weaver C, Leonardi-Bee J, May J, Fox S, Willmot M. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and lecocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 2005;93:527-534.
17. Menon N, Wolf A, Zehetgruber M, Bing R. An improved chemiluminescence assay suggests non nitric oxide mediated action of lysophoshatidylcholine and acetylcholine. Proc Soc Exp Biol Med 1989;191:316-319.
18. Rashid PA, Whitehurst A, Lawson N, Bath PMW. Plasma nitric oxide (nitrate/nitrite) levels in acute stroke and their relationship with severity and outcome. J Stroke Cerebrovasc Dis 2003;12:82-87.
19. Sano T, Motomiya T, Yamazaki H. Platelet release reaction in vivo in patients with ischaemic heart disease after isometric exercise and its prevention with dipyridamole. Thromb Haemost 1980;42:1589-1597.
20. Lauri D, Zanetti A, Dejana E. Effects of dipyridamole and low-dose aspirin therapy on platelet adhesion to vascular subendothelium. Am J Cardiol 1986;58:1261-1264.
21. Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel walls cells. Neurology 2001;57(Suppl 2):S20-S23.
22. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982;95:355-360.
23. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989;73:1109-1112.
24. Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000;96:3322-3328.
25. Bult H, Fret HR, Jordaens FH, Herman AG. Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991;199:1-8.
26. Aktas B, Utz A, Hoenig-Liedl P, Walter U, Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke 2003;34:764-769.
27. Moreno L, Losada B, Cogolludo AL, Lodi F, Lugnier C, Villamor E, Moro M, Tamargo J, Perez-Vizcaino F. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: Activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr Res 2004.
28. Tohgi H, Takahashi H, Chiba K, Tamura K. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke 1993;24:801-804.
29. Peters H, Eisenberg R, Daig U, Liefeldt L, Westenfeld R, Gaedeke J, Kramer S, Neumayer HH. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thyl glomerulonephritis. Kidney Int 2004;65:2238-2248.
30. Konkle BA, Schick PK, He X, Liu RJ, Mazur EM. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler Thromb 1993;13:669-674.
31. Mousa SA, Bozarth J, Forsythe M, Tsao P, Pease L, Reilly TM. Role of platelet GpIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sci 1994;54:1155-1162.
32. Cha JK, Jeong MH, Lee KM, Bae HR, Lim YJ, Park KW, Cheon SM. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002;14:145-150.
33. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004;2:1934-1940.
34. Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ, Ellis SG, Topol EJ. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358-360.
35. Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol 2001;24:705-709.
36. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000;9:37-41.
37. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: A placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-2041.
38. Correa RC, Alfieri AB. Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications. J Diabetes Complications 2003;17:264-268.
39. Blann AD, Dobrotova M, Kubisz P, McCollum CN. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626-630.
40. Bath PMW, Blann A, Smith N, Butterworth RJ. Von Willebrand factor, p-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998;9:155-159.